IL-22在乙型肝炎肝硬化失代偿期患者中表达的临床分析

doi:10.3969/j.issn.1672-5069.2016.06.028

Abstract

Cen Yu，Su Sibiao，et al.. IL-22 expression and its clinical significance in patients with hepatitis B virus-induced decompensated liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 734-735.

References

[1] 韩莹，丁惠国. 抗病毒治疗乙型肝炎肝硬化的过去、现在和将来. 实用肝脏病杂志，2015，18（5）:453-456.
[2] Lin J，Wu JF，Zhang Q，et al. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol， 2014，20（21）:6457-6469.
[3] Hernandez-Gea V，Friedman SL. Pathogenesis of liver fibrosis. Ann Rev Pathol，2011，6:425-456.
[4] 李咏，陆玉蕾，吴婷，等. IL-22和SOCS3在3型鼠肝炎病毒诱导的小鼠慢性病毒性肝炎发病中的作用探讨. 实用肝脏病杂志，2014，17（4）: 400-403.
[5] Foster RG，Golden-Mason L，Rutebemberwa A，et al. Interleukin （IL）-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral （HCV） infection. Dig Dis Sci，2012，57（2）:381-389.
[6] Zhang Y，Cobleigh MA，Lian JQ，et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology，2011，141（5）:1897-1906.
[7] Xiang X，Gui H，King NJC，et al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol，2012，90（6）:611-619.
[8] 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）:81-89.
[9] Ren X，Hu B，Colletti LM. IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol Gastrointest Liver Physiol，2010，298（1）:G74-80.
[10] Feng D，Kong X，Weng H，et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology，2012，143（1）:188-198.e187.
[11] Radaeva S，Sun R，Pan HN，et al. Interleukin 22 （IL-22） plays a protective role in T cell-mediated murine hepatitis:IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology，2004，39（5）:1332-1342.
[12] Xing WW，Zou MJ，Liu S，et al. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci Biotechnol Biochem，2011，75（7）:1290-1294.
[13] Rountree CB，Mishra L，Willenbring H. Stem cells in liver diseases and cancer:recent advances on the path to new therapies. Hepatology，2012，55（1）:298-306.
[14] Jiang R，Tan Z，Deng L，et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology，2011，54（3）:900-909.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.

IL-22 expression and its clinical significance in patients with hepatitis B virus-induced decompensated liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments